TY  - JOUR
A1  - Frantz, Stefan
A1  - Falcao-Pires, Ines
A1  - Balligand, Jean-Luc
A1  - Bauersachs, Johann
A1  - Brutsaert, Dirk
A1  - Ciccarelli, Michele
A1  - Dawson, Dana
A1  - de Windt, Leon J.
A1  - Giacca, Mauro
A1  - Hamdani, Nazha
A1  - Hilfiker-Kleiner, Denise
A1  - Hirsch, Emilio
A1  - Leite-Moreira, Adelino
A1  - Mayr, Manuel
A1  - Thum, Thomas
A1  - Tocchetti, Carlo G.
A1  - van der Velden, Jolanda
A1  - Varricchi, Gilda
A1  - Heymans, Stephane
T1  - The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC
JF  - European Journal of Heart Failure
N2  - Activation of the immune system in heart failure (HF) has been recognized for over 20 years. Initially, experimental studies demonstrated a maladaptive role of the immune system. However, several phase III trials failed to show beneficial effects in HF with therapies directed against an immune activation. Preclinical studies today describe positive and negative effects of immune activation in HF. These different effects depend on timing and aetiology of HF. Therefore, herein we give a detailed review on immune mechanisms and their importance for the development of HF with a special focus on commonalities and differences between different forms of cardiomyopathies. The role of the immune system in ischaemic, hypertensive, diabetic, toxic, viral, genetic, peripartum, and autoimmune cardiomyopathy is discussed in depth. Overall, initial damage to the heart leads to disease specific activation of the immune system whereas in the chronic phase of HF overlapping mechanisms occur in different aetiologies.
KW  - immune system
KW  - macrophage
KW  - T-cell
KW  - ischaemic cardiomyopathy
KW  - hypertensive cardiomyopathy
KW  - diabetic cardiomyopathy
KW  - toxic cardiomyopathy
KW  - viral cardiomyopathy
KW  - genetic cardiomyopathy
KW  - peripartum cardiomyopathy
KW  - autoimmune cardiomyopathy
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-229091
VL  - 20
ER  - 
TY  - JOUR
A1  - Werner, Rudolf A.
A1  - Eissler, Christoph
A1  - Hayakawa, Nobuyuki
A1  - Arias-Loza, Paula
A1  - Wakabayashi, Hiroshi
A1  - Javadi, Mehrbod S.
A1  - Chen, Xinyu
A1  - Shinaji, Tetsuya
A1  - Lapa, Constantin
A1  - Pelzer, Theo
A1  - Higuchi, Takahiro
T1  - Left Ventricular Diastolic Dysfunction in a Rat Model of Diabetic Cardiomyopathy using ECG-gated \(^{18}\)F-FDG PET
JF  - Scientific Reports
N2  - In diabetic cardiomyopathy, left ventricular (LV) diastolic dysfunction is one of the earliest signs of cardiac involvement prior to the definitive development of heart failure (HF). We aimed to explore the LV diastolic function using electrocardiography (ECG)-gated \(^{18}\)F-fluorodeoxyglucose positron emission tomography (\(^{18}\)F-FDG PET) imaging beyond the assessment of cardiac glucose utilization in a diabetic rat model. ECG-gated \(^{18}\)F-FDG PET imaging was performed in a rat model of type 2 diabetes (ZDF fa/fa) and ZL control rats at age of 13 weeks (n=6, respectively). Under hyperinsulinemic-euglycemic clamp to enhance cardiac activity, \(^{18}\)F-FDG was administered and subsequently, list-mode imaging using a dedicated small animal PET system with ECG signal recording was performed. List-mode data were sorted and reconstructed into tomographic images of 16 frames per cardiac cycle. Left ventricular functional parameters (systolic: LV ejection fraction (EF), heart rate (HR) vs. diastolic: peak filling rate (PFR)) were obtained using an automatic ventricular edge detection software. No significant difference in systolic function could be obtained (ZL controls vs. ZDF rats: LVEF, 62.5±4.2 vs. 59.4±4.5%; HR: 331±35 vs. 309±24 bpm; n.s., respectively). On the contrary, ECG-gated PET imaging showed a mild but significant decrease of PFR in the diabetic rats (ZL controls vs. ZDF rats: 12.1±0.8 vs. 10.2±1 Enddiastolic Volume/sec, P<0.01). Investigating a diabetic rat model, ECG-gated \(^{18}\)F-FDG PET imaging detected LV diastolic dysfunction while systolic function was still preserved. This might open avenues for an early detection of HF onset in high-risk type 2 diabetes before cardiac symptoms become apparent.
KW  - diabetic cardiomyopathy
KW  - personalized treatment
KW  - precision medicine
KW  - ZDF rats
KW  - ECG
KW  - PET
KW  - \(^{18}\)F-fluorodeoxyglucose
KW  - \(^{18}\)F-FDG
KW  - diabetes
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-171765
VL  - 8
IS  - 17631
ER  -